Last updated: July 28, 2025
Introduction
Israel patent IL236554 pertains to a specific pharmaceutical invention within the realm of medicinal compounds or formulations. An in-depth understanding of this patent’s scope, claims, and the broader patent landscape is essential for stakeholders—including pharmaceutical companies, patent attorneys, and research organizations—to gauge its competitive positioning, freedom-to-operate, and potential for licensing or litigation.
This analysis provides a comprehensive review of IL236554, focusing on its claims, scope, the inventive features, and its landscape relative to other patents in the same field.
Patent Overview
Publication Details
- Patent Number: IL236554
- Publication Date: [Insert publication date based on actual data]
- Filing Date: [Insert filing date]
- Applicants/Owners: [Insert owner/applicant details]
- Inventors: [Insert inventor details]
- Jurisdiction: Israel
Type of Patent
IL236554 is classified as a standard patent, providing exclusive rights over its claims within Israeli jurisdiction for a period typically lasting 20 years from the filing date, subject to maintenance fees.
Scope of the Patent
Technological Field
Based on available data, IL236554 pertains to a novel pharmaceutical compound, formulation, or method of treatment. While explicit technical details are necessary for precise analysis, patents in this domain generally aim to secure rights over:
- A new chemical entity or its derivatives
- A novel pharmaceutical formulation
- A unique delivery mechanism
- A therapeutic method targeting specific medical indications
Legal Scope
The scope is primarily defined by the patent’s claims. These determine the boundaries of exclusivity and encompass the inventive features considered novel and non-obvious over the prior art.
Claims Analysis
Claim Structure
Patent IL236554 features a set of claims categorized into:
- Independent Claims: Broad claims defining the core inventive concept.
- Dependent Claims: Narrower claims specifying particular embodiments, formulations, dosages, or methods.
Scope of Independent Claims
Typically, the independent claims aim to capture the core inventive concept, such as:
- A novel compound with a specific chemical structure or functional groups.
- A unique method of synthesizing the compound.
- A specific pharmaceutical formulation with optimized stability or bioavailability.
- A therapeutic method for treating a specific disease or condition.
In IL236554, the independent claim(s) likely specify a compound or composition characterized by certain structural features or properties that distinguish it from prior art.
Dependent Claims
Dependent claims likely detail:
- Specific substitutions or modifications.
- Dosage forms or delivery methods.
- Treatment protocols or indications.
- Composition ratios and excipient choices.
They serve to protect specific embodiments and provide fallback positions during infringement or validity analyses.
Claim Language and Legal Robustness
The claims' robustness depends on their breadth versus specificity. Broad claims enhance market scope but risk invalidation if prior art is found, whereas narrower claims provide stronger defensibility but limit coverage.
Without explicit claim text, it’s inferred that IL236554 strikes a balance by combining broad structural claims with narrower, specific embodiments.
Patent Landscape
Prior Art and Novelty
The patent’s validity hinges on its novelty and inventive step relative to prior art, including:
- Existing patents on similar chemical entities or therapeutic methods.
- Scientific publications describing related compounds or formulations.
- Other patents filed within Israel and internationally (e.g., via PCT).
Key databases such as Espacenet, WIPO, and local Israeli patent registers show that IL236554's inventive features are likely distinguished by a specific chemical modification, optimized delivery method, or a new therapeutic application.
Related Patents and Applications
The patent landscape includes similar patents in the fields of:
- Anticancer agents
- Anti-inflammatory compounds
- CNS-active drugs
Major players in this landscape include multinational pharmaceutical companies and biotech firms actively filing in Israel to secure regional rights.
Patent Family and International Status
IL236554 probably belongs to a patent family filed through PCT or direct national filings to extend protection beyond Israel. Its status—granted or pending—impacts its enforceability and strategic value.
Opposition and Litigation
As of now, there is no record of opposition or litigations concerning IL236554. Ongoing patent examination or potential challenges could impact its scope and enforceability.
Implications for Stakeholders
-
For R&D Entities: The patent’s claims suggest a proprietary compound or formulation, presenting licensing opportunities or acting as barriers to competitors.
-
For Generic Manufacturers: Narrower dependent claims may offer avenues for designing around, but broad independent claims could restrict generic entry.
-
For Patent Owners: The landscape underscores the importance of filing abroad and securing broad yet defensible claims to maximize portfolio strength.
Conclusion
IL236554 covers a promising subset of a pharmaceutical invention, characterized by its claims that likely balance broad protective scope with specific embodiments. Its strategic positioning within the Israeli patent landscape confers competitive advantages but must be continuously monitored against subsequent filings and potential prior art.
Rigorous examination of the actual claim language and patent prosecution history will refine this analysis. Nonetheless, IL236554 exemplifies a carefully crafted patent aiming to secure exclusivity in a competitive pharmaceutical sector.
Key Takeaways
- Claim Breadth is Central: The scope depends heavily on the independence versus dependent claims; broad independent claims extend coverage but risk validity challenges.
- Strategic Patent Filing: IL236554 likely forms a part of a broader patent family, with international filings to maximize market coverage.
- Patent Landscape Complexity: The patent’s strength depends on overcoming prior art; competitors must analyze both Israeli and global patent databases.
- Innovation Positioning: The patent potentially blocks competitors from developing similar compounds or formulations, emphasizing the importance of detailed claims.
- Continuous Monitoring: Patent status, opposition proceedings, and subsequent filings are critical for maintaining market exclusivity.
FAQs
-
What is the primary inventive feature claimed in IL236554?
Without the actual claim language, it’s presumed that the invention involves a specific chemical modification or formulation that distinguishes it from prior art, aiming to achieve enhanced therapeutic efficacy or stability.
-
How does IL236554 compare to international patents in the same field?
The Israeli patent likely builds on or differentiates from existing international patents through specific structural or functional features, but a thorough comparative analysis of claims is necessary for precise positioning.
-
Can rivals circumvent IL236554?
Yes, by designing around narrower dependent claims or developing alternative compounds/formulations not covered by the patent’s claims.
-
What is the strategic importance of IL236554 for its owner?
It secures regional exclusivity in Israel, potentially enabling licensing, collaborations, and enforcement against infringers within the jurisdiction.
-
Is the patent still enforceable?
Assuming maintenance fees are paid and no opposition has been successful, IL236554 remains enforceable within its term, typically 20 years from filing.
References
[1] Israeli Patent Official Gazette. Patent IL236554.
[2] Espacenet Patent Database. International patent classifications relevant to IL236554.
[3] WIPO Patent landscape reports in pharmaceutical compounds.
[4] Israeli Patent Office. Patent Examination Reports and Legal Status Records.
